<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialRecordsOutput xmlns:ns2="local"><serviceExecutionTime>260</serviceExecutionTime><Trial id="128834"><TitleDisplay>A Longitudinal, Observational Study of Patients with Early Rheumatoid Arthritis</TitleDisplay><TitleOfficial>The TACERA Study: a longitudinal observational study of patients with early rheumatoid arthritis</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">UKCRN ID 12364</Identifier><Identifier type="Other">ISRCTN28793839</Identifier><Identifier type="Trial Acronym">TACERA</Identifier></Identifiers><Indications><Indication id="291">Rheumatoid arthritis</Indication></Indications><BiomarkerNames><BiomarkerName id="46" role="Disease marker" type="Genomic;Proteomic">C-reactive protein</BiomarkerName><BiomarkerName id="745" role="Disease marker" type="Proteomic">Rheumatoid factor</BiomarkerName><BiomarkerName id="746" role="Disease marker" type="Proteomic">Anti-cyclic citrullinated peptides antibodies</BiomarkerName><BiomarkerName id="781" role="Disease marker" type="Physiological">Erythrocyte sedimentation rate</BiomarkerName><BiomarkerName id="1388" role="Disease marker" type="Genomic;Proteomic">Myeloblastin</BiomarkerName><BiomarkerName id="30214" role="Disease marker" type="Physiological;Structural (imaging)">Joint swelling</BiomarkerName><BiomarkerName id="30217" role="Disease marker" type="Physiological;Structural (imaging)">Joint tenderness</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>immunological toolkit</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1042032" type="Company"><TargetEntity id="5035525916" type="organizationId">National Institute for Health Research</TargetEntity></SourceEntity><SourceEntity id="18438" type="Company"><TargetEntity id="5035523380" type="organizationId">Medical Research Council</TargetEntity></SourceEntity><SourceEntity id="23507" type="Company"><TargetEntity id="4296365401" type="organizationId">King's College London</TargetEntity></SourceEntity><SourceEntity id="26229" type="Company"><TargetEntity id="5035524006" type="organizationId">Guys and St Thomas Hospital NHS Trust</TargetEntity></SourceEntity><SourceEntity id="291" type="ciIndication"><TargetEntity id="10039073" type="MEDDRA"></TargetEntity><TargetEntity id="D001172" type="MeSH"></TargetEntity><TargetEntity id="-1391695545" type="omicsDisease"></TargetEntity><TargetEntity id="749" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="23507">King's College London</Company><Company id="26229">Guy's &amp; St Thomas' Hospital NHS Trust</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1042032">National Institute for Health Research (NIHR)</Company><Company id="18438">Medical Research Council</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Longitudinal</Term><Term>Cohort</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>275</PatientCountEnrollment><DateStart>2012-09-30T00:00:00Z</DateStart><DateEnd type="actual">2015-07-10T00:00:00Z</DateEnd><DateChangeLast>2018-03-02T06:58:45Z</DateChangeLast><DateAdded>2013-05-10T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>King's College London</Affiliation><Email>andrew.cope@kcl.ac.uk</Email><Name>Andrew Cope</Name></Contact><Contact type="Public contact"><Affiliation>Kings College London</Affiliation><Email>gemma.simpson1@nhs.net ,</Email><Name>Gemma Simpson</Name><Phone>0207 848 5206</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients should fulfill either 1987 American College of Rheumatology (ACR) or 2010 American College of Rheumatology/European League Against Rheumatism classification criteria (ACR/EULAR) classification criteria for diagnosis of early RA&lt;/li&gt;&lt;li&gt;Positive for serum rheumatoid factor and anti-citrullinated protein autoantibodies (ACPA)&lt;/li&gt;&lt;li&gt;Within 6 months of symptom onset&lt;/li&gt;&lt;li&gt;Supervising rheumatologist considers that starting therapy with DMARDs is appropriate&lt;/li&gt;&lt;li&gt;At least 18 years of age&lt;/li&gt;&lt;li&gt;Able and willing to give informed consent to provide clinical data and blood samples at defined time points for the duration of the study&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Previous treatment with DMARDs or biologicals&lt;/li&gt;&lt;li&gt;Corticosteroid treatment for the current episode of inflammatory arthritis within the last 6 months (patients with a previous episode of inflammatory arthritis treated with corticosteroids more than 6 months before screening will be permitted providing this episode was not ongoing)&lt;/li&gt;&lt;li&gt;Use of intramuscular steroid injections between the first clinic attendance (when the diagnosis of RA is made) and study entry&lt;/li&gt;&lt;li&gt;Significant co-morbidities (eg, severe congestive heart failure, renal, hepatic, malignant disease), as judged by the supervising physician&lt;/li&gt;&lt;li&gt;Pregnant or wishing to conceive&lt;/li&gt;&lt;li&gt;Participating in trials of investigational medicinal products or devices, or other interventions (eg, exercise) which may have an impact on the patient's treatment or disease activity&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Disease remission: this will be measured using either the long established DAS28 criterion (DAS28 score &lt; 2.6) or the Simplified Disease Activity Index (SDAI) &lt;/= 3.3, or the new ACR/EULAR 2010 remission criteria: swollen joint count &lt;/= 1, tender joint count &lt;/= 1,  CRP &lt;/= 1 (mg/dl) and patient global &lt;/= 1 (on a 1 to 10 scale)</Description><Timeframe>At 6 months</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Extended (66/68) joint count DAS28</Description></Measure><Measure><Description>Simple Disease Activity Score (SDAI)</Description></Measure><Measure><Description>Clinical Disease Activity Score (CDAI)</Description></Measure><Measure><Description>Health Assessment Questionnaire (HAQ) scores</Description></Measure><Measure><Description>EQ5D scores</Description></Measure><Measure><Description>SF-36</Description></Measure><Measure><Description>Radiographic progression of hands and feet X-rays scored by Larsen's or van der Heijde Sharpe Modified Scores</Description></Measure><Measure><Description>Disease remission (as defined in primary outcome measure)</Description><Timeframe>At 12 and 18 months</Timeframe></Measure><Measure><Description>Immune signatures derived from the analysis of biological samples</Description></Measure><Measure><Description>To define predictors of clinical response and define what true remission is in patients with early RA</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study was to define predictors of clinical response and define what true remission was in patients with early rheumatoid arthritis (RA). Patients newly diagnosed with RA would be treated conventionally according to national institute for health and care excellence (NICE) guidelines.  The plan was to use this information to develop an ‘immunological toolkit’ to help predict which patients would respond well to particular treatments so that patients can be treated with individualized drug combinations that are most likely to induce and sustain remission  [&lt;ulink linkType="Reference" linkID="1417566"&gt;1417566&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The investigators  hypothesis was that a suite of immunological assays (hereafter termed 'the immunological toolkit') can be used to accurately predict clinical responses to therapy at a molecular and cellular level also propose that immune-based assays can be adapted to define an immune signature associated with a state of sustained clinical remission in patients with early RA.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;The study would recruit 410 patients within 4 weeks of diagnosis. They would be disease modifying antirheumatic drugs (DMARD) naive and would  not have received corticosteroid treatment for the current episode of inflammatory arthritis. In addition all patients  would be positive for Rheumatoid Factor and Anti-citrullinated protein antibody (ACPA). Patients would receive standard treatment following national guidelines throughout the study period. The study duration would be 18 months. Patients would be assessed at months 0, 3, 6, 9, 12, 15 and 18 using standard validated questionnaires and blood tests as set out in current guidelines for all DMARDs and TNF-inhibitors. Biological sampling (blood and urine) would be carried out at each assessment for the purpose of developing an ‘immunological toolkit’. X-rays of hands and feet would be taken at baseline, 0, 12 and 18 months  [&lt;ulink linkType="Reference" linkID="1417566"&gt;1417566&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;The investigators would  observe how arthritis responds to standard therapy in patients who has been diagnosed with early RA, within 6 months of symptom onset, would  receive treatment according to NICE guidelines and would be attending assessments at every 3 months in a 18 months study. At each study assessment the following would  take place.&lt;br/&gt;Patients would  complete the following with the research nurse: disease activity score (DAS28 and extended swollen and tender joint counts 66/68, patient global assessment), HAQ (Health assessment questionnaire measuring disability) and lifestyle factors questionnaire.&lt;br/&gt;The following questionnaires would be completed at baseline, 6, 12 and 18 months only: SF36 (Quality of life questionnaire), EQ5D (Health outcome questionnaire), FACIT-F questionnaire (Functional assessment of Chronic Illness Therapy), IPQ-R-RA (Illness Perception Questionnaire) and MAPLe-RA (Measuring Actual Patient-Led expectations).&lt;br/&gt;The following would be reviewed: concomitant diseases and medication, current medication and adverse events.&lt;br/&gt;The following samples would be taken: blood samples for routine safety monitoring and ESR and CRP values and blood and urine samples for the immunoanalysis. HRUS (High Resolution Ultrasonography) would be undertaken at baseline, 6 and 12 months (an 18 month scan would  be optional). This ultasound based imaging would be optional and would  be offered to patients at those recruiting centers  that provide this service as part of routine clinical care. Patients may also be telephoned by their research nurse in between study visits to check how well their disease is being controlled by their medication.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="UK"><Sites><Site><Contacts></Contacts></Site><Site><Contacts></Contacts></Site><Site><Name>Birmingham City Hospital</Name><Contacts></Contacts></Site><Site><Name>Cannock Chase Hospital</Name><Contacts></Contacts></Site><Site><Name>Chapel Allerton</Name><Contacts></Contacts></Site><Site><Name>Croydon University Hospital</Name><Contacts></Contacts></Site><Site><Name>Darlington Memorial Hospital</Name><Contacts></Contacts></Site><Site><Name>Doncaster Royal Infirmary</Name><Contacts></Contacts></Site><Site><Name>Freeman Hospital</Name><Contacts></Contacts></Site><Site><Name>Gartnaval General Hospital</Name><Contacts></Contacts></Site><Site><Name>Glasgow Royal Infirmary</Name><Contacts></Contacts></Site><Site><Name>Guy's Hospital</Name><Contacts></Contacts></Site><Site><Name>Homerton University Hospital</Name><Contacts></Contacts></Site><Site><Name>King's College Hospital</Name><Contacts></Contacts></Site><Site><Name>Manchester Royal Infirmary</Name><Contacts></Contacts></Site><Site><Name>Mile-End Hospital</Name><Contacts></Contacts></Site><Site><Name>Northwick Park Hospital</Name><Contacts></Contacts></Site><Site><Name>Nuffield Orthopedic Hospital</Name><Contacts></Contacts></Site><Site><Name>Poole Hospital</Name><Contacts></Contacts></Site><Site><Name>Queen Elizabeth Hospital Gateshead</Name><Contacts></Contacts></Site><Site><Name>Queen Elizabeth Hospital, Woolwich</Name><Contacts></Contacts></Site><Site><Name>Queen's Hospital Burton</Name><Contacts></Contacts></Site><Site><Name>Queen's Medical Centre</Name><Contacts></Contacts></Site><Site><Name>Royal Free Hospital</Name><Contacts></Contacts></Site><Site><Name>Royal Surrey County Hospital</Name><Contacts></Contacts></Site><Site><Name>Russells Hall Hospital</Name><Contacts></Contacts></Site><Site><Name>The Great Western Hospital</Name><Contacts></Contacts></Site><Site><Name>The James Cook University Hospital</Name><Contacts></Contacts></Site><Site><Name>University College London Hospital</Name><Contacts></Contacts></Site><Site><Name>University Elizabeth Hospital</Name><Contacts></Contacts></Site><Site><Name>University Hospital Lewisham</Name><Contacts></Contacts></Site><Site><Name>University Hospital of North Durham</Name><Contacts></Contacts></Site><Site><Name>Wishaw General Hospital</Name><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Rheumatoid arthritis</Disease><PatientSegments><PatientSegment><PatientSegment id="497">Very Early/Early Rheumatoid Arthritis</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="514">Treatment Naive Subjects</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="545">Subjects with Sero-Positive Rheumatoid Arthritis</PatientSegment><SubSegments><SubSegment id="534">Rheumatoid factor (RF)</SubSegment><SubSegment id="546">Anti-cyclic citrullinated peptide antibody (anti-CCP)</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1002">International Standard Randomised Controlled Trial Number Register (ISRCTN)</Name><Identifiers><Identifier>ISRCTN28793839</Identifier></Identifiers></Registry><Registry><Name id="1023">UK Clinical Research Network (UKCRN)</Name><Identifiers><Identifier type="Secondary Organisational">UKCRN ID 12364</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><OtherEndpoints><OtherEndpoint disease="Rheumatoid arthritis" id="3959"><Endpoint>Assessment of Remission</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Rheumatoid arthritis" id="1914"><Criterion>ACR Functional Status Classification for Rheumatoid Arthritis</Criterion></Inclusion><Inclusion disease="Rheumatoid arthritis" id="1919"><Criterion>Very Early/Early Rheumatoid Arthritis</Criterion></Inclusion><Inclusion disease="Rheumatoid arthritis" id="1928"><Criterion>Subjects with Seropositive Rheumatoid Arthritis</Criterion><SubCriteria><SubCriterion disease="Rheumatoid arthritis" id="1929">Seropositive for RF</SubCriterion><SubCriterion disease="Rheumatoid arthritis" id="1998">Anti-Cyclic Citrullinated Peptide Antibody (anti-CCP)</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Rheumatoid arthritis" id="1945"><Criterion>Treatment Naive Subjects</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Rheumatoid arthritis" id="2845"><Criterion>Subjects with History of Use of Rheumatoid Arthritis Therapy</Criterion><SubCriteria><SubCriterion disease="Rheumatoid arthritis" id="2846">Subjects with history of biological DMARDs</SubCriterion><SubCriterion disease="Rheumatoid arthritis" id="2849">Subjects with history of corticosteroids</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Rheumatoid arthritis" id="2870"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Rheumatoid arthritis" id="2898"><Criterion>Subjects co-morbid with Hepatic Disorders/Diseases</Criterion></Exclusion><Exclusion disease="Rheumatoid arthritis" id="2903"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Rheumatoid arthritis" id="2915"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Rheumatoid arthritis" id="25800"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Rheumatoid arthritis" id="2981">Subjects with history of DMARDs</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><DateEnrollmentEnd type="actual">2015-07-10T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>33.39 Months</EnrollmentPeriod><EnrollmentRate>8.24 Patients/Month</EnrollmentRate><FundersType><Type>Academic</Type><Type>Company</Type><Type>Government</Type></FundersType><ChangeHistory><Change type="added"><Date>2013-05-10T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change><Change type="updated"><Date>2018-03-02T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="180972"><TitleDisplay>JACTAX LD Drug Eluting Stent Trial</TitleDisplay><TitleOfficial>A Clinical Trial Comparing the Performance of the JACTAX LD DES With the TAXUS Liberte DES</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT00754975</Identifier><Identifier type="Organisational Study">LBCT-H02-07</Identifier></Identifiers><Indications><Indication id="80">Coronary artery disease</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>JACTAX LD DES</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>TAXUS Liberte DES</Name></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1005229" type="Company"><TargetEntity id="4298133136" type="organizationId">Labcoat Ltd</TargetEntity></SourceEntity><SourceEntity id="27847" type="Company"><TargetEntity id="4295903586" type="organizationId">Boston Scientific Corp</TargetEntity></SourceEntity><SourceEntity id="80" type="ciIndication"><TargetEntity id="10011078" type="MEDDRA"></TargetEntity><TargetEntity id="D003327" type="MeSH"></TargetEntity><TargetEntity id="-1572475765" type="omicsDisease"></TargetEntity><TargetEntity id="221" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>5</NumberOfSites><CompaniesSponsor><Company id="27847">Boston Scientific Corp</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1005229">Labcoat Ltd</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>130</PatientCountEnrollment><DateStart>2008-01-31T00:00:00Z</DateStart><DateEnd type="actual">2010-07-31T00:00:00Z</DateEnd><DateChangeLast>2017-03-17T13:43:46Z</DateChangeLast><DateAdded>2014-04-13T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Elizabeth Hospital, Essen Germany</Affiliation><Name>Eberhard Grube</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;General:&lt;ul&gt;&lt;li&gt;Patient is &gt;/= 18 years of age&lt;/li&gt;&lt;li&gt;Patient with coronary artery disease, eligible for percutaneous coronary intervention (PCI)&lt;/li&gt;&lt;li&gt;Patient demonstrates a LVEF of &gt;/= 25%&lt;/li&gt;&lt;li&gt;Patient or legal guardian understands and agrees to comply with all specified study requirements and provides written informed consent to this effect&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Angiographic:&lt;ul&gt;&lt;li&gt;Target lesion is de novo native coronary artery lesion (ie, a coronary lesion not previously treated)&lt;/li&gt;&lt;li&gt;The target lesion can be treated with a maximum of one stent, with adequate coverage onto the healthy tissue, as specified in visual estimate guidelines. Maximum lesion length is 20 mm&lt;/li&gt;&lt;li&gt;The reference vessel diameter is between 2.75 and 3.5 mm&lt;/li&gt;&lt;li&gt;Study lesion diameter stenosis is &gt;/= 70 (visual estimate) and&amp;lt;/= 100% and a TIMI flow &gt; 1&lt;/li&gt;&lt;li&gt;Study lesion has been successfully predilated&lt;/li&gt;&lt;li&gt;Patients enrolled for treatment may demonstrate multiple lesions in target vessel. However lesions must be covered completely by one study stent&lt;/li&gt;&lt;li&gt;Patient must have no more than two lesions requiring treatments. These lesions must be in different vessel distributions. For example, if the target lesion is in the LAD, then the non target lesion must be present in either the circumflex or RCA. The nonstudy lesion may not be in a branch vessel or distal to the target vessel location&lt;/li&gt;&lt;li&gt;The non target lesion must be successfully treated prior to the treatment of the target lesion. The non target lesion must be treated with a TAXUS paclitaxel eluting stent or a bare metal stainless steel stent&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;General:&lt;ul&gt;&lt;li&gt;The patient has a life expectancy of&amp;lt; 24 months due to another medical condition&lt;/li&gt;&lt;li&gt;Patient has a history of hypersensitivity to paclitaxel or structurally related compounds&lt;/li&gt;&lt;li&gt;Patient exhibits cardiogenic shock (systolic pressure&amp;lt;/= 80 and PCWP &gt; 20 mmHg or cardiac index &amp;lt;/= 1.8 l/min/m or intra-aortic balloon pump or intravenous inotropes are needed to maintain a systolic pressure &gt; 80 mmHg) for any time within 24 h prior to index procedure&lt;/li&gt;&lt;li&gt;Patient demonstrates evidence of acute or chronic renal dysfunction (serum creatinine &gt; 2.0 mg/dl or 177 umol/l)&lt;/li&gt;&lt;li&gt;Planned cardiac surgery procedure&amp;lt;/= 9 months post index procedure&lt;/li&gt;&lt;li&gt;Patient demonstrates evidence of myocardial infarction (elevated CK, CKMB or Troponin) within 72 h prior to the index procedure and/or CK &gt; 2 x local lab's ULN, unless CK-MB is&amp;lt;/= 2 x ULN&lt;/li&gt;&lt;li&gt;Patient exhibits acute ST segment elevation MI within 72 h prior to the index procedure&lt;/li&gt;&lt;li&gt;CVA including stroke or TIA within previous 3 months&lt;/li&gt;&lt;li&gt;Patient demonstrates evidence of leukopenia&lt;/li&gt;&lt;li&gt;Patient demonstrates evidence of thrombocytopenia or thrombocytosis&lt;/li&gt;&lt;li&gt;Patient is contraindicated to ASA, clopidogrel or ticlopidine&lt;/li&gt;&lt;li&gt;Patient is currently taking warfarin or possibility of treatment with warfarin during the following 6 months post index procedure&lt;/li&gt;&lt;li&gt;Patient has been treated with paclitaxel or other chemotherapeutic agents within 12 months prior to planned index procedure&lt;/li&gt;&lt;li&gt;Anticipated treatment with paclitaxel or oral rapamycin during any period in the 9 months after the index procedure&lt;/li&gt;&lt;li&gt;Patient has received a drug eluting stent within 12 months prior to planned index procedure&lt;/li&gt;&lt;li&gt;Previous or planned treatment with intravascular brachytherapy in target vessel&lt;/li&gt;&lt;li&gt;Known allergy to stainless steel&lt;/li&gt;&lt;li&gt;Male or female with known intention to procreate within 3 months after the index procedure&lt;/li&gt;&lt;li&gt;Female of child-bearing potential with a positive pregnancy test within 7 days before the index procedure or lactating or intends to become pregnant during the 9 months post index procedure&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Angiographic:&lt;ul&gt;&lt;li&gt;Evidence of probable or definite thrombus of the study vessel, based on angiography or IVUS&lt;/li&gt;&lt;li&gt;Study lesion is totally occluded (TIMI flow&amp;lt;/= 1)either at baseline or before predilatation&lt;/li&gt;&lt;li&gt;Study lesion or the study vessel proximal to the study lesion is moderately or severely calcified by visual estimate&lt;/li&gt;&lt;li&gt;Study lesion is ostial in location (within 3.0 mm of vessel origin)&lt;/li&gt;&lt;li&gt;Study lesion involving arterial segments with highly tortuous anatomy or where lesion is located within or distal to a &gt; 60 degree bend in the vessel&lt;/li&gt;&lt;li&gt;Study lesion involves a bifurcation with a diseased (&gt;50% stenotic) branch vessel &gt; 2.0 mm in diameter&lt;/li&gt;&lt;li&gt;Left main coronary artery disease (stenosis &gt; 50%) whether protected or unprotected&lt;/li&gt;&lt;li&gt;Target lesion length &gt; 20 mm based on visual estimate by operator&lt;/li&gt;&lt;li&gt;Target vessel diameter &gt; 3.5 mm based on visual estimate by operator&lt;/li&gt;&lt;li&gt;Target vessel diameter&amp;lt;/= 2.75 mm based on visual estimate by operator&lt;/li&gt;&lt;li&gt;Pretreatment of the target lesion (excluding predilation) with another interventional device&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Major Adverse Cardiac Events (MACE) rate</Description><Timeframe>9 months</Timeframe></Measure></MeasuresPrimary><MeasureSecondary></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study  was to evaluate      the efficacy of the JACTAX LD stent and to compare it with the TAXUS Liberte stent.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients  	would be randomized in a 2 : 1 ratio to receive either the JACTAX LD or the TAXUS Liberte stent.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Germany"><Sites><Site><Name>Cardiovascular Center Sankt Katharinen</Name><Address1>Frankfurt</Address1><Contacts></Contacts></Site><Site><Name>HELIOS Klinikum</Name><Address1>Siegburg</Address1><Contacts></Contacts></Site><Site><Name>Hamburg University CardioVascular Center</Name><Address1>Hamburg</Address1><Contacts></Contacts></Site><Site><Name>Universitatsklinikum Bonn</Name><Address1>Bonn</Address1><Contacts></Contacts></Site><Site><Name>Krankehaus Der Barmherzigen Bruder</Name><Address1>Trier</Address1><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Coronary artery disease</Disease><PatientSegments><PatientSegment><PatientSegment id="201">Subjects Undergoing/Underwent Percutaneous Coronary Intervention (PCI)</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="234">Subjects with Specified Thrombolysis in Myocardial Infarction (TIMI) Flow Grades</PatientSegment><SubSegments><SubSegment id="237">TIMI Flow Grade 2</SubSegment><SubSegment id="238">TIMI Flow Grade 3</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="239">Subjects with Abnormal Echo/ECG findings</PatientSegment><SubSegments><SubSegment id="240">Abnormal left ventricular ejection fraction</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="243">Subjects with Abnormal Angiographic Findings</PatientSegment><SubSegments><SubSegment id="245">De novo lesion/lesions</SubSegment><SubSegment id="251">Stenosis/Narrowing of vessel</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00754975</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Coronary artery disease" id="2491"><Endpoint>Assessment of Cardiovascular Events</Endpoint><SubEndpoints><SubEndpoint disease="Coronary artery disease" id="2495">Ischemia Driven Major Adverse Cardiac Event (MACE)</SubEndpoint><SubEndpoint disease="Coronary artery disease" id="2619">Assessment of major adverse cardiac events (MACEs)</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Coronary artery disease" id="1068"><Criterion>Subjects with Coronary Artery Disease (CAD)</Criterion></Inclusion><Inclusion disease="Coronary artery disease" id="1169"><Criterion>Subjects with History of /Scheduled for Coronary Revascularization Therapy</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1171">PTCA (percutaneous transluminal coronary angioplasty)/Stent placement</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Coronary artery disease" id="1180"><Criterion>Subjects with Abnormal ECG/ Echocardiographic Findings</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1181">Left ventricular ejection fraction &gt;25% and &lt;35%</SubCriterion><SubCriterion disease="Coronary artery disease" id="1182">Left ventricular ejection fraction &gt;35% and &lt;50%</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Coronary artery disease" id="1191"><Criterion>Subjects assessed with Thrombolysis in Myocardial Infarction (TIMI) Flow Grades</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1194">Grade 2 (Partial perfusion)</SubCriterion><SubCriterion disease="Coronary artery disease" id="1195">Grade 3 (Complete perfusion)</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Coronary artery disease" id="1201"><Criterion>Coronary Angiogram Findings Suggestive of/Confirmed CAD/CHD</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1205">De novo lesion/lesions</SubCriterion><SubCriterion disease="Coronary artery disease" id="1209">Lesions that can be covered by a single stent</SubCriterion><SubCriterion disease="Coronary artery disease" id="1213">Target vessel having multiple lesions</SubCriterion><SubCriterion disease="Coronary artery disease" id="1218">Lesion in native coronary artery</SubCriterion><SubCriterion disease="Coronary artery disease" id="1220">Stenosis in non-target/non-culprit lesions</SubCriterion><SubCriterion disease="Coronary artery disease" id="1222">Stenosis of target lesion is ≥ 50% &amp; ≤ 100 by visual estimate</SubCriterion><SubCriterion disease="Coronary artery disease" id="1224">Target reference vessel dimensions suitable for stent placement</SubCriterion><SubCriterion disease="Coronary artery disease" id="1434">Successful predialation of the study lesion</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Coronary artery disease" id="1602"><Criterion>Subjects with Myocardial Infarction (MI)</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1606">Acute ST segment elevation myocardial infarction (STEMI)</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Coronary artery disease" id="1609"><Criterion>Subjects with Specific Coronary Angiographic Findings</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1614">Aorto-ostial location of lesion</SubCriterion><SubCriterion disease="Coronary artery disease" id="1616">Calcified lesions</SubCriterion><SubCriterion disease="Coronary artery disease" id="1617">Chronic total occlusion/TIMI flow 0 or TIMI flow 1 prior to wire crossing</SubCriterion><SubCriterion disease="Coronary artery disease" id="1620">Excessive tortuosity/angulation proximal to or within the lesion</SubCriterion><SubCriterion disease="Coronary artery disease" id="1622">Involves a bifurcation lesion</SubCriterion><SubCriterion disease="Coronary artery disease" id="1623">Left main artery location (protected /Unprotected)</SubCriterion><SubCriterion disease="Coronary artery disease" id="1628">Prior coronary intervention</SubCriterion><SubCriterion disease="Coronary artery disease" id="1632">Target lesion is located within or distal to a &gt;45° to&gt; 60° bend in the vessel</SubCriterion><SubCriterion disease="Coronary artery disease" id="1634">Thrombus in target vessel</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Coronary artery disease" id="1651"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1657">Subjects co-morbid with cardiogenic shock</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Coronary artery disease" id="1696"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Coronary artery disease" id="1740"><Criterion>Subjects co-morbid with Hematological/Coagulation Disorders</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1749">Subjects co-morbid with heparin induced thrombocytopenia</SubCriterion><SubCriterion disease="Coronary artery disease" id="1751">Thrombocytosis</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Coronary artery disease" id="1780"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="5588">Subjects co-morbid with cerebrovascular/CNS disorder</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Coronary artery disease" id="1842"><Criterion>Subjects with History of/Scheduled for Diagnostic/Therapeutic Procedures</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1853">Recent history/planned major surgery</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Coronary artery disease" id="1857"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1866">Creatine Kinase(CK) above the Upper Limit of Normal</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Coronary artery disease" id="26090"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1844">Brachytherapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Coronary artery disease" id="26158"><Criterion>Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1805">Anticoagulant therapy</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2009-05-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2008-09-16T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-04-13T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="249386"><TitleDisplay>Expression of Altered Glycosyltransferases, Mucins and RTKs in Human Ovarian and Endometrial Cancers</TitleDisplay><TitleOfficial>Expression of Altered Glycosyltransferases, Mucins and RTKs in Human Ovarian and Endometrial Cancers</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02638402</Identifier><Identifier type="Organisational Study">201405068RINA</Identifier></Identifiers><Indications><Indication id="1705">Endometrioid carcinoma</Indication><Indication id="3866">Metastatic ovary cancer</Indication></Indications><BiomarkerNames><BiomarkerName id="8" role="Disease marker" type="Genomic;Proteomic">Epidermal growth factor receptor</BiomarkerName><BiomarkerName id="13" role="Disease marker" type="Genomic;Proteomic">Proto-oncogene tyrosine-protein kinase Src</BiomarkerName><BiomarkerName id="89" role="Disease marker" type="Genomic;Proteomic">Hepatocyte growth factor receptor</BiomarkerName><BiomarkerName id="1103" role="Disease marker" type="Genomic">Polypeptide N-acetylgalactosaminyltransferase 2</BiomarkerName><BiomarkerName id="4056" role="Disease marker" type="Genomic;Proteomic">Alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase A</BiomarkerName><BiomarkerName id="6050" role="Disease marker" type="Genomic">Glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase 1</BiomarkerName><BiomarkerName id="6281" role="Disease marker" type="Genomic;Proteomic">Mucin-1</BiomarkerName><BiomarkerName id="8470" role="Disease marker" type="Genomic;Proteomic">Mucin-17</BiomarkerName><BiomarkerName id="9492" role="Disease marker" type="Genomic;Proteomic">beta-1,4-Galactosyltransferase 1</BiomarkerName><BiomarkerName id="10949" role="Disease marker" type="Genomic;Proteomic">Polypeptide N-acetylgalactosaminyltransferase 6</BiomarkerName><BiomarkerName id="11837" role="Disease marker" type="Genomic;Proteomic">Vascular endothelial growth factor receptors</BiomarkerName><BiomarkerName id="15561" role="Disease marker" type="Genomic;Proteomic">beta-1,4-Galactosyltransferase 3</BiomarkerName><BiomarkerName id="15996" role="Disease marker" type="Genomic;Proteomic">Mucin-15</BiomarkerName><BiomarkerName id="16324" role="Disease marker" type="Genomic;Proteomic">Mucin-20</BiomarkerName><BiomarkerName id="16490" role="Disease marker" type="Genomic;Proteomic">beta-1,4-Mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase</BiomarkerName><BiomarkerName id="20090" role="Disease marker" type="Genomic;Proteomic">N-acetyl-beta-glucosaminyl-glycoprotein 4-beta-N-acetylgalactosaminyltransferase 2</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>immunohistochemical expression profiling</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1038961" type="Company"><TargetEntity id="5039106413" type="organizationId">National Taiwan University Hospital</TargetEntity></SourceEntity><SourceEntity id="1705" type="ciIndication"><TargetEntity id="10014733" type="MEDDRA"></TargetEntity><TargetEntity id="D016889" type="MeSH"></TargetEntity><TargetEntity id="-49801714" type="omicsDisease"></TargetEntity><TargetEntity id="597" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3866" type="ciIndication"><TargetEntity id="10057529" type="MEDDRA"></TargetEntity><TargetEntity id="629" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="1038961">National Taiwan University Hospital</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Female</Term></TermsPatientSelection><TrialCategories><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Case Control</Term><Term>Retrospective</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>250</PatientCountEnrollment><DateStart>2016-05-31T00:00:00Z</DateStart><DateEnd type="estimated">2017-08-31T00:00:00Z</DateEnd><DateChangeLast>2017-05-04T11:25:25Z</DateChangeLast><DateAdded>2015-12-29T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>National Taiwan University Hospital</Affiliation><Email>chihau@ntuh.gov.tw</Email><Name>Chi-Hau Chen, MD, PhD</Name><Phone>+886-972651980</Phone></Contact><Contact type="Scientific contact"><Affiliation>National Taiwan University Hospital</Affiliation><Email>chihau@ntuh.gov.tw</Email><Name>Chi-Hau Chen, MD, PhD</Name><Phone>+886-972651980</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Ovarian and endometrial cancer patients receiving operation in National Taiwan University Hospital&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Recurrence or non-operable patients&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Measure the immunohistochemistry (IHC) expression</Description><Timeframe>Five years after patient received surgery</Timeframe></Measure></MeasuresPrimary><MeasureSecondary></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this trial is to clarify the critical role of glycosyltransferases, altered mucins, and RTKs in human      ovarian and endometrial neoplasms, the study will examine the immunohistochemical expression      profiles of glycosyltransferases, mucins and receptor tyrosin kinases (RTKs) family in      various stages and/or histological subtypes of human ovarian and endometrial neoplasms and      tissue microarrays.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Stage I, II, III, IV ovarian  and endometrial cancer patients who are receiving operation in &lt;ulink linkType="Company" linkID="1038961"&gt;National Taiwan University Hospital&lt;/ulink&gt; will be included and observed in this trial. The study will involve patients undergoing immunohistochemical expression profiling of glycosyltransferases (including beta-1,4-Galactosyltransferase 1 [B4GALT1], beta-1,4-Galactosyltransferase 3 [B4GALT3], beta-1,4-N-Acetyl-Galactosaminyl Transferase 3 [B4GALNT3], Polypeptide N-Acetylgalactosaminyltransferase 2 [GALNT2], Polypeptide N-Acetylgalactosaminyltransferase 6 [GALNT6], beta-1,4-N-acetylglucosaminyltransferase III [GlcNAcT-III], beta-1,4-N-acetylglucosaminyltransferase V [GlcNAcT-V], and Glycoprotein-N-Acetylgalactosamine 3-Beta-Galactosyltransferase 1 [C1GALT1], Mucins [including MUC1, MUC3, MUC15, and MUC20] and receptor tyrosin kinases [RTKs] family[(including epidermal growth factor receptor [EGFR], Src, VEGFR, and c-Met) in various stages and/or histological subtypes of human ovarian and endometrial neoplasms and tissue microarrays, and compare them with clinicopathological factors including outcome of the patients&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries></SitesByCountries><PatientSegmentTerms></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02638402</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Ovary tumor" id="10845"><Endpoint>Assessment of Immune Response</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Endometrioid carcinoma" id="12892"><Endpoint>Assessment of Immune Function</Endpoint></PrimaryEndpoint></PrimaryEndpoints><OtherEndpoints><OtherEndpoint disease="Ovary tumor" id="10926"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint><SubEndpoints><SubEndpoint disease="Ovary tumor" id="10937">Genetic analysis</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Endometrioid carcinoma" id="12846"><Endpoint>Assessment of Biomarkers</Endpoint></OtherEndpoint><OtherEndpoint disease="Endometrioid carcinoma" id="12885"><Endpoint>Pharmacogenetic/Pharmacogenomics Analysis</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Endometrioid carcinoma" id="8090"><Criterion>Subjects with History of Anti Cancer Therapy</Criterion><SubCriteria><SubCriterion disease="Endometrioid carcinoma" id="8096">Subjects with history of surgery/procedure for Endometrial Cancer</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Ovary tumor" id="8273"><Criterion>Subjects with History of Anti Cancer Therapy</Criterion><SubCriteria><SubCriterion disease="Ovary tumor" id="8279">Subjects with history of surgery/procedure for Ovarian Cancer</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Ovary tumor" id="9779"><Criterion>Subjects with Recurrent or Persistent Ovarian Cancer</Criterion></Exclusion><Exclusion disease="Ovary tumor" id="12435"><Criterion>Subjects with Unresectable Tumor</Criterion></Exclusion><Exclusion disease="Endometrioid carcinoma" id="26379"><Criterion>Subjects by disease severity</Criterion><SubCriteria><SubCriterion disease="Endometrioid carcinoma" id="9632">Subjects with Unresectable Endometrial Cancer</SubCriterion><SubCriterion disease="Endometrioid carcinoma" id="9671">Subjects with Relapsed/Recurrent Endometrial Cancer</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2016-08-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2015-12-20T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2015-12-29T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="286886"><TitleDisplay>A propensity score analysis to evaluate the safety and efficacy of metformin in patients with pancreatic ductal adenocarcinoma (PDAC) and pre-existing diabetes</TitleDisplay><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers></Identifiers><Indications><Indication id="1507">Pancreatic ductal adenocarcinoma</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>metformin hydrochloride</Name><Drug id="6050">metformin hydrochloride</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="6050">metformin hydrochloride</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1042246">U.S. Department of Health and Human Services</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="20518">National Institutes of Health</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="20519">National Cancer Institute</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="6050" type="Drug"><TargetEntity id="220882" type="siDrug">Metformin hydrochloride</TargetEntity></SourceEntity><SourceEntity id="1042246" type="Company"><TargetEntity id="8589934547" type="organizationId">US Department of Health &amp; Human Services</TargetEntity></SourceEntity><SourceEntity id="20518" type="Company"><TargetEntity id="5001347606" type="organizationId">National Institutes of Health</TargetEntity></SourceEntity><SourceEntity id="20519" type="Company"><TargetEntity id="4296539077" type="organizationId">National Cancer Institute</TargetEntity></SourceEntity><SourceEntity id="1507" type="ciIndication"><TargetEntity id="D021441" type="MeSH"></TargetEntity><TargetEntity id="1858" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="8805" type="Action"><TargetEntity id="2375" type="Mechanism">AMP-Activated Protein Kinase (AMPK) Activators</TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="12">Status not specified</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="1042246">U.S. Department of Health and Human Services</Company><Company id="20518">National Institutes of Health</Company><Company id="20519">National Cancer Institute</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="8805">AMP activated protein kinase stimulator</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1545">Anticancer</Class><Class id="38206">Biguanide antidiabetic product</Class><Class id="399">Hypoglycemic agent</Class></Class><Technologies><Technology id="751">Film coating</Technology><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TrialCategories><Category>Small molecule</Category></TrialCategories><PatientCountEnrollment>1916</PatientCountEnrollment><PatientCountEvaluable>1916</PatientCountEvaluable><DateChangeLast>2017-02-03T16:00:12Z</DateChangeLast><DateAdded>2017-02-05T00:00:00Z</DateAdded><Contacts></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients diagnosed with pancreatic ductal adenocarcinoma&lt;/li&gt;&lt;li&gt;Patients with pre-existing diabetes mellitus (DM) &lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary></MeasuresPrimary><MeasureSecondary><Measure><Description>To evaluate the association between metformin use and overall survival: by using inverse propensity weighted Cox proportional-hazard model</Description></Measure><Measure><Description>Mortality risk</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;In September 2016, results were published. After the adjustment of confounders including diabetic to comorbidity severity index (DCSI), Charlson score, and chronic kidney disease (CKD), metformin users showed 12% decreased risk of mortality than non-users (ie, patients on other medications; p &amp;lt; 0.01)    [&lt;ulink linkType="Reference" linkID="1897323"&gt;1897323&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this propensity score analysis was to evaluate whether &lt;ulink linkType="Drug" linkID="6050"&gt;metformin&lt;/ulink&gt; use before pancreatic ductal adenocarcinoma (PDAC) diagnosis affected survival of patients with diabetes mellitus (DM), controlling confounders such as diabetic severity  [&lt;ulink linkType="Reference" linkID="1897323"&gt;1897323&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In September 2016, results were published. Mean survival duration in metformin users versus non-users were 5.5 versus 4.2 months, respectively  (p &amp;lt;0.01).  Irrespective of the Charlson score, the DCSI score, the presence of kidney disease, or the use of insulin/other hypoglycemic medications, differences were persisted in stratified analysis    [&lt;ulink linkType="Reference" linkID="1897323"&gt;1897323&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients who received treatment with (n = 1098; users) or without (n = 818; non-users) metformin were analyzed   [&lt;ulink linkType="Reference" linkID="1897323"&gt;1897323&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries></SitesByCountries><PatientSegmentTerms></PatientSegmentTerms><TrialRegistries></TrialRegistries><OutcomeMeasureTerms></OutcomeMeasureTerms><FundersType><Type>Government</Type></FundersType><ChangeHistory><Change type="added"><Date>2017-02-05T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="289945"><TitleDisplay>Effect Of Belt Electrode Skeletal Muscle Electrical Stimulation To Physical Function And Psychological Fatigue For Hemodialysis Patients</TitleDisplay><TitleOfficial>Effect Of Belt Electrode Skeletal Muscle Electrical Stimulation To Physical Function And Psychological Fatigue For Hemodialysis Patients</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">UMIN000026408</Identifier></Identifiers><Indications><Indication id="829">Fatigue</Indication></Indications><BiomarkerNames><BiomarkerName id="147" role="Therapeutic effect marker" type="Physiological">Six-minute walk distance</BiomarkerName><BiomarkerName id="19714" role="Therapeutic effect marker" type="Physiological">Muscle strength</BiomarkerName><BiomarkerName id="40656" role="Therapeutic effect marker" type="Physiological">Knee extension strength</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Hemodialysis</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>belt electrode skeletal muscle electrical stimulation</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1144547" type="Company"><TargetEntity id="5054815024" type="organizationId">Shutaikai Hospital</TargetEntity></SourceEntity><SourceEntity id="829" type="ciIndication"><TargetEntity id="10016256" type="MEDDRA"></TargetEntity><TargetEntity id="D005221" type="MeSH"></TargetEntity><TargetEntity id="-961418346" type="omicsDisease"></TargetEntity><TargetEntity id="2620" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1144547">Syutaikai Hospital</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Non-Randomized</Term><Term>No Control</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>20</PatientCountEnrollment><DateStart>2016-07-01T00:00:00Z</DateStart><DateChangeLast>2018-03-12T03:51:37Z</DateChangeLast><DateAdded>2017-03-07T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Syutaikai Hospital ; Rehabilitation center
</Affiliation><Email>reha.noguchi.ot@gmail.com</Email><Name>Yuta Noguchi</Name><Phone>059-354-1771</Phone></Contact><Contact type="Scientific contact"><Affiliation>Syutaikai Hospital ; Rehabilitation center
</Affiliation><Email>reha.noguchi.ot@gmail.com</Email><Name>Yuta Noguchi</Name><Phone>059-354-1771</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Hemodialysis patients&lt;/li&gt;&lt;li&gt;Frailty patients&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Cardiac pace maker&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Grip strength, knee extension strength, Berg balance scale, chair stand 30, 10 m walking test, 6 min walk distance</Description></Measure><Measure><Description>Visual Analog Scale</Description></Measure><Measure><Description>Profile of Mood States-Brief Form</Description></Measure></MeasuresPrimary><MeasureSecondary></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;Investigators examined the effect of belt electrode skeletal muscle electrical stimulation during dialysis on physical functions and psychological fatigue.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Eligible patients would receive belt electrode skeletal muscle electrical stimulation once per week for   3 months.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Japan"><Sites><Site><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>End stage renal disease</Disease><PatientSegments><PatientSegment><PatientSegment id="7704">Subjects with Dialysis Dependant Chronic Kidney Disease(DD-CKD)</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Other musculoskeletal disease</Disease><PatientSegments><PatientSegment><PatientSegment id="18266">Subjects with specific disease</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1003">University Hospital Medical Information Network (UMIN)</Name><Identifiers><Identifier type="Secondary Organisational">UMIN000026408</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Other musculoskeletal disease" id="42991"><Endpoint>Assessment of Functional Disability/Physical Function</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Other musculoskeletal disease" id="42994"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></PrimaryEndpoint></PrimaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="End stage renal disease" id="17648"><Criterion>Subjects with Dialysis Dependant Chronic Kidney Disease(DD-CKD)</Criterion></Inclusion><Inclusion disease="Other musculoskeletal disease" id="32742"><Criterion>Subjects with History of/Scheduled for Therapy for other Indication</Criterion></Inclusion><Inclusion disease="Other musculoskeletal disease" id="35079"><Criterion>Subjects with specific disease</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="End stage renal disease" id="17551"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion></Exclusion><Exclusion disease="Other musculoskeletal disease" id="24185"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2017-03-07T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2018-03-12T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="309003"><TitleDisplay>HITT Device Pilot Testing for Traumatic Brain Injury</TitleDisplay><TitleOfficial>Feasibility Study of Head and Intraocular Trauma Test (HITT) Device for Potential Detection of Brain Dysfunction</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03249818</Identifier><Identifier type="Organisational Study">rebiscan-004</Identifier></Identifiers><Indications><Indication id="3733">Traumatic brain injury</Indication></Indications><BiomarkerNames><BiomarkerName id="54816" role="Disease marker" type="Physiological">Eye movement</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Head and Intraocular Trauma Test (HITT) system</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1118950" type="Company"><TargetEntity id="5050265388" type="organizationId">Rebiscan Inc</TargetEntity></SourceEntity><SourceEntity id="20658" type="Company"><TargetEntity id="5000724109" type="organizationId">University of Pennsylvania</TargetEntity></SourceEntity><SourceEntity id="3733" type="ciIndication"><TargetEntity id="10060690" type="MEDDRA"></TargetEntity><TargetEntity id="1188" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1118950">Rebiscan Inc</Company></CompaniesSponsor><CompaniesCollaborator><Company id="20658">University of Pennsylvania</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Open Label</Term><Term>Diagnosis</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>7</PatientCountEnrollment><DateStart>2017-08-22T00:00:00Z</DateStart><DateEnd type="actual">2018-02-28T00:00:00Z</DateEnd><DateChangeLast>2018-10-12T02:31:50Z</DateChangeLast><DateAdded>2017-08-21T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>University of Pennsylvania</Affiliation><Email>Ramon.Diaz-Arrastia@uphs.upenn.edu</Email><Name>Ramon Diaz-Arrastia, MD, PhD</Name><Phone>215-662-9732</Phone></Contact><Contact type="Scientific contact"><Affiliation>University of Pennsylvania</Affiliation><Email>Ramon.Diaz-Arrastia@uphs.upenn.edu</Email><Name>Ramon Diaz-Arrastia, MD, PhD</Name><Phone>215-662-9732</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Age &gt;/= 18 to 40 years&lt;/li&gt;&lt;li&gt;Documented/ verified mild TBI&lt;/li&gt;&lt;li&gt;Mild traumatic brain injury will be defined as Glasgow Coma Scale (GCS) of &gt;/= 13 at time of study enrollment&lt;/li&gt;&lt;li&gt;Injury occurred&amp;lt; 24 h ago&lt;/li&gt;&lt;li&gt;Positive acute brain CT for clinical care&lt;/li&gt;&lt;li&gt;Visual acuity/ hearing adequate for testing&lt;/li&gt;&lt;li&gt;Fluency in English or Spanish&lt;/li&gt;&lt;li&gt;Ability to provide informed consent&lt;/li&gt;&lt;li&gt;Enrolled in TRACK-TBI (IRB no: 825503)&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Catastrophic polytrauma that would interfere with follow-up and outcome assessment&lt;/li&gt;&lt;li&gt;Prisoners or patients in custody&lt;/li&gt;&lt;li&gt;Pregnancy in female subjects&lt;/li&gt;&lt;li&gt;Patients on psychiatric hold (e.g. 5150, 5250)&lt;/li&gt;&lt;li&gt;Major debilitating baseline mental health disorders (e.g. schizophrenia or bipolar disorder) that would interfere with follow-up and the validity of outcome assessment&lt;/li&gt;&lt;li&gt;Major debilitating neurological disease (e.g. stroke, dementia, tumor) impairing baseline awareness, cognition, or validity of follow-up and outcome assessment&lt;/li&gt;&lt;li&gt;Significant history of pre-existing conditions that would interfere with follow-up and outcome assessment (eg, substance abuse, alcoholism, HIV/AIDS, major transmittable diseases that may interfere with consent, end-stage cancers, learning disabilities, developmental disorders)&lt;/li&gt;&lt;li&gt;Low likelihood of follow-up (e.g. participant or family indicating low interest, homelessness or lack of reliable contacts)&lt;/li&gt;&lt;li&gt;Penetrating TBI&lt;/li&gt;&lt;li&gt;Spinal cord injury with ASIA (American Spinal Injury Assoc.) score of C or worse&lt;/li&gt;&lt;li&gt;Any injury to eye including, puncture, scratch, occlusion, fracture to orbital socket (or any fracture to face that would negatively impact eye movement/vision) that would interfere with ability to complete study-device assessment&lt;/li&gt;&lt;li&gt;History of poor vision prior to injury (Visual acuity worse than 20/40 in either eye)&lt;/li&gt;&lt;li&gt;Intoxication or chemical impairment at time of examination (upon initial presentation)&lt;/li&gt;&lt;li&gt;Evidence on hand-light examination of obvious ocular anomaly or misalignment&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>TBI detection: patients who have diagnosed TBI and are admitted to the hospital for treatment will have their eyes scanned to identify whether the HITT device can accurately identify patients with TBI</Description><Timeframe>1 day</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>TBI monitor: patients who have remained in the hospital for TBI and received initial HITT device scan will receive a second set of scans at 2 weeks to identify whether the HITT device can accurately identify patients with TBI</Description><Timeframe>14 days</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this research study was to collect data from the eyes of traumatic brain injury      (TBI) patients.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would look at a green target that would measure the fixation of the      eye for 30 s. In that 30 s, the location of the green target would change and the      patient is to track, with their eyes, the light as best they can. The device would measure      how well fixation would be  maintained and the speed of the saccadic movements of the eye. HITT device to scan eyes of patient three times (30 s each) at time of admittance to hospital for diagnosed traumatic brain injury. Device would scan the fovea of the eye to measure fixation. Patients would then be asked to track the fixation target across an area the size of a playing card, with the device tracking the patient's fixation throughout. If patient would be  still in hospital 2 weeks post-enrollment, a second set of three tests would be performed. Data      would then be used to determine whether there is correlation between these measures and known      TBI.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Penn Presbyterian Medical Center</Name><Address1>Philadelphia</Address1><Address2>Pennsylvania</Address2><Address3>19104</Address3><CountrySubDivision code="PA">Pennsylvania</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Other neurological disease</Disease><PatientSegments><PatientSegment><PatientSegment id="17728">Subjects with specific disease</PatientSegment><SubSegments><SubSegment id="15969">Subjects with Traumatic Brain Injury</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03249818</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Other neurological disease" id="43051"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Other neurological disease" id="45172"><Endpoint>Clinical Assessments</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Other neurological disease" id="43051"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Other neurological disease" id="45172"><Endpoint>Clinical Assessments</Endpoint></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Other neurological disease" id="46419"><Endpoint>Protocol Specified Other Endpoints</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Other neurological disease" id="32685"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Other neurological disease" id="32805"><Criterion>Subjects with Protocol Specified Visual Acuity</Criterion></Inclusion><Inclusion disease="Other neurological disease" id="33192"><Criterion>Subjects with specific disease</Criterion></Inclusion><Inclusion disease="Other neurological disease" id="34308"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Other neurological disease" id="32748">Subjects able/willing to provide written informed consent</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Other neurological disease" id="34796"><Criterion>Subjects with Protocol Specified Symptom Scales/Scores</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Other neurological disease" id="24024"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Other neurological disease" id="24397">Subjects with infectious diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Other neurological disease" id="24386"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion></Exclusion><Exclusion disease="Other neurological disease" id="24392"><Criterion>Subjects with abnormal/unacceptable neuropsychological assessment</Criterion></Exclusion><Exclusion disease="Other neurological disease" id="24402"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion></Exclusion><Exclusion disease="Other neurological disease" id="24963"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Other neurological disease" id="24095">Pregnancy/Lactation/Women of childbearing potential/Intend to become pregnant/Without adequate contraception</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Other neurological disease" id="25618"><Criterion>Subjects with Protocol Specified Participation Status</Criterion></Exclusion><Exclusion disease="Other neurological disease" id="25821"><Criterion>Subjects co-morbid with CNS disorders</Criterion></Exclusion><Exclusion disease="Other neurological disease" id="26002"><Criterion>Subjects co-morbid with neurological disorders/diseases</Criterion><SubCriteria><SubCriterion disease="Other neurological disease" id="24634">Subjects co-morbid with dementia</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Other neurological disease" id="26702"><Criterion>Subjects co-morbid with Psychiatric Disease/Disorder</Criterion><SubCriteria><SubCriterion disease="Other neurological disease" id="24385">Subjects co-morbid with alcohol and/or drug/substance abuse</SubCriterion><SubCriterion disease="Other neurological disease" id="24637">Subjects with mood disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Other neurological disease" id="27919"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Other neurological disease" id="24149">Subjects unwilling/unable to comply with the study protocol</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2018-02-28T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2017-08-09T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2017-08-21T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2017-10-03T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2018-09-11T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="319169"><TitleDisplay>Role of LDH as a Predictor of Treatment Outcomes in Hepatocellular Carcinoma</TitleDisplay><TitleOfficial>Role of LDH as a Predictor of Treatment Outcomes in Hepatocellular Carcinoma</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03338166</Identifier><Identifier type="Organisational Study">URL</Identifier></Identifiers><Indications><Indication id="1767">Hepatocellular carcinoma</Indication></Indications><BiomarkerNames><BiomarkerName id="154" role="Therapeutic effect marker" type="Genomic;Proteomic">Lactate dehydrogenase</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>LDH serum level test</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>sorafenib</Name><Drug id="29831">sorafenib</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>surgery</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>trans catheter arterial chemo embolization (TACE)</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="29831">sorafenib</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1025024">Assiut University</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="29831" type="Drug"><TargetEntity id="301618" type="siDrug">Sorafenib</TargetEntity></SourceEntity><SourceEntity id="1025024" type="Company"><TargetEntity id="5035537586" type="organizationId">Assiut University</TargetEntity></SourceEntity><SourceEntity id="1767" type="ciIndication"><TargetEntity id="D006528" type="MeSH"></TargetEntity><TargetEntity id="88673" type="ORPHANET"></TargetEntity><TargetEntity id="-1116061312" type="omicsDisease"></TargetEntity><TargetEntity id="1973" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1722" type="Action"><TargetEntity id="1103" type="Mechanism">VEGFR Inhibitors</TargetEntity><TargetEntity id="1619" type="Mechanism">Anti-VEGF</TargetEntity><TargetEntity id="1788" type="Mechanism">Vascular Endothelial Growth Factor (VEGF) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="3806" type="Action"><TargetEntity id="1628" type="Mechanism">Flt3 (FLK2/STK1) Inhibitors</TargetEntity><TargetEntity id="1910" type="Mechanism">Anti-CD135 (flt-3)</TargetEntity></SourceEntity><SourceEntity id="3808" type="Action"><TargetEntity id="1704" type="Mechanism">KIT (C-KIT) Inhibitors</TargetEntity><TargetEntity id="3405" type="Mechanism">Anti-c-KIT</TargetEntity><TargetEntity id="5665" type="Mechanism">KIT (C-KIT) (Asp816Val Mutant) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="3846" type="Action"><TargetEntity id="1308" type="Mechanism">VEGFR-1 (Flt-1) Inhibitors</TargetEntity><TargetEntity id="2609" type="Mechanism">Anti-VEGFR-1 (Flt-1)</TargetEntity></SourceEntity><SourceEntity id="3848" type="Action"><TargetEntity id="1309" type="Mechanism">VEGFR-2 (FLK-1/KDR) Inhibitors</TargetEntity><TargetEntity id="1786" type="Mechanism">Anti-VEGFR-2 (KDR)</TargetEntity></SourceEntity><SourceEntity id="3850" type="Action"><TargetEntity id="1627" type="Mechanism">VEGFR-3 (FLT4) Inhibitors</TargetEntity><TargetEntity id="2518" type="Mechanism">Anti-VEGFR-3 (FLT4)</TargetEntity></SourceEntity><SourceEntity id="4542" type="Action"><TargetEntity id="1212" type="Mechanism">Raf Kinase Inhibitors</TargetEntity></SourceEntity><SourceEntity id="4548" type="Action"><TargetEntity id="2892" type="Mechanism">Raf kinase B Inhibitors</TargetEntity></SourceEntity><SourceEntity id="4550" type="Action"><TargetEntity id="2963" type="Mechanism">Raf kinase C Inhibitors</TargetEntity></SourceEntity><SourceEntity id="48492" type="Action"><TargetEntity id="1651" type="Mechanism">PDGFRbeta Inhibitors</TargetEntity><TargetEntity id="1831" type="Mechanism">Anti-CD140b (PDGFRbeta)</TargetEntity></SourceEntity><SourceEntity id="948" type="Action"><TargetEntity id="1072" type="Mechanism">PDGFR Family Inhibitors</TargetEntity><TargetEntity id="1789" type="Mechanism">Platelet-Derived Growth Factor (PDGF) Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1025024">Assiut University</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="1722">VEGF receptor antagonist</Action><Action id="3806">Flt3 tyrosine kinase inhibitor</Action><Action id="3808">Kit tyrosine kinase inhibitor</Action><Action id="3816">RET tyrosine kinase receptor family inhibitor</Action><Action id="3846">VEGF-1 receptor antagonist</Action><Action id="3848">VEGF-2 receptor antagonist</Action><Action id="3850">VEGF-3 receptor antagonist</Action><Action id="4542">Raf protein kinase inhibitor</Action><Action id="4548">Raf B protein kinase inhibitor</Action><Action id="4550">Raf 1 protein kinase inhibitor</Action><Action id="48492">PDGF receptor beta antagonist</Action><Action id="948">PDGF receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1545">Anticancer</Class><Class id="61">Angiogenesis inhibitor</Class><Class id="62255">Anticancer protein kinase inhibitor</Class></Class><Technologies><Technology id="751">Film coating</Technology><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Cohort</Term><Term>Prospective</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>50</PatientCountEnrollment><DateStart>2018-01-02T00:00:00Z</DateStart><DateEnd type="estimated">2018-12-31T00:00:00Z</DateEnd><DateChangeLast>2018-01-05T10:18:42Z</DateChangeLast><DateAdded>2017-11-15T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Email>samir_eid@hotmail.com</Email><Name>Samir S Mohammed, Professor</Name><Phone>00201222302375</Phone></Contact><Contact type="Scientific contact"><Affiliation>Assiut University</Affiliation><Name>Aml R Ibrahim, Lecturer</Name></Contact><Contact type="Public contact"><Email>esmail_marwa@yahoo.com</Email><Name>Marwa I Khalaf, Lecturer</Name><Phone>00201201777338</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with hepatocellular carcinoma diagnosed by biopsy or imaging criteria and alpha feto protein&lt;/li&gt;&lt;li&gt;Signed informed consent before registration in study&lt;/li&gt;&lt;li&gt;Eastern cooperative oncology groups performance status between 0 and 2&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Cachexia or poor condition&lt;/li&gt;&lt;li&gt;Pregnant or human chorionic gonadotropin positive&lt;/li&gt;&lt;li&gt;Patient with another liver tumor&lt;/li&gt;&lt;li&gt;Any previous treatment&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Serum LDH level as a predictor of response in hepatocellular carcinoma: to evaluate if serum LDH level can be used as a predictor of response in patients receiving different lines of treatment for hepatocellular carcinoma</Description><Timeframe>2 months</Timeframe></Measure></MeasuresPrimary><MeasureSecondary></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This study aims to  investigate the role of    LDH as a predictor of treatment outcomes in hepatocellular carcinoma.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients resident at oncology department at Luxor international hospital who diagnosed as apatient with hepatocellular carcinoma will be enrolled and observed for this study.&lt;br/&gt;This  study consist of following groups:&lt;br/&gt;Group A: patients with hepatocellular carcinoma who  treated with &lt;ulink linkType="Drug" linkID="29831"&gt;sorafenib&lt;/ulink&gt; and measure  LDH serum level one month pre and post treatment.&lt;br/&gt;Group B: patients with hepatocellular carcinoma who  treated with trans catheter arterial chemo embolization (TACE) and measure LDH serum level one month pre and post treatment.&lt;br/&gt;Group C: patients with hepatocellular carcinoma who  treated surgically and measure LDH serum level one month pre and post treatment.&lt;br/&gt;Group D: patients with hepatocellular carcinoma who dont receive treatment and asses LDH serum level for 3months.&lt;br/&gt;Blood sample to measure LDH as a predictor of hepatocellular carcinoma treatment outcome.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Assiut University</Name><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Hepatobiliary system tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="18937">Subjects with specific disease</PatientSegment><SubSegments><SubSegment id="16345">Subjects with hepatocellular carcinoma</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03338166</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Hepatobiliary system tumor" id="12096"><Endpoint>Assessment of Biomarkers</Endpoint><SubEndpoints><SubEndpoint disease="Hepatobiliary system tumor" id="12099">Assessment of Serum Biomarkers</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Hepatobiliary system tumor" id="12127"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></PrimaryEndpoint></PrimaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Hepatobiliary system tumor" id="7848"><Criterion>Subjects with Elevated Alpha-fetoprotein (AFP) levels</Criterion></Inclusion><Inclusion disease="Hepatobiliary system tumor" id="7863"><Criterion>Subjects with Protocol Specified Performance Status </Criterion><SubCriteria><SubCriterion disease="Hepatobiliary system tumor" id="7864">Subjects with ECOG/WHO/Zubrod score performance status of 0</SubCriterion><SubCriterion disease="Hepatobiliary system tumor" id="7865">Subjects with ECOG/WHO/Zubrod score performance status of 1</SubCriterion><SubCriterion disease="Hepatobiliary system tumor" id="7866">Subjects with ECOG/WHO/Zubrod score performance status of 2</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Hepatobiliary system tumor" id="7889"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Hepatobiliary system tumor" id="34259"><Criterion>Subjects with specific disease</Criterion><SubCriteria><SubCriterion disease="Hepatobiliary system tumor" id="32046">Subjects with hepatocellular carcinoma</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Hepatobiliary system tumor" id="34412"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Hepatobiliary system tumor" id="7891">Subjects willing/able to provide informed consent/assent</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Hepatobiliary system tumor" id="9411"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Hepatobiliary system tumor" id="9412"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Hepatobiliary system tumor" id="9439"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion></Exclusion><Exclusion disease="Hepatobiliary system tumor" id="9451"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Hepatobiliary system tumor" id="9462">Protocol specified exclusion criteria for females</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2018-07-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2017-06-17T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2017-11-15T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="340410"><TitleDisplay>Nonarthritic Hip Disease Evaluation And Treatment</TitleDisplay><TitleOfficial>Informed Decisions and Patient Outcomes: An Interdisciplinary Approach to Chronic Hip Pain</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03519087</Identifier><Identifier type="Organisational Study">2017H0340</Identifier><Identifier type="Trial Acronym">NEAT</Identifier></Identifiers><Indications><Indication id="542">Joint disease</Indication></Indications><BiomarkerNames><BiomarkerName id="49025" role="Therapeutic effect marker" type="Physiological">Hip strength</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>interdisciplinary evaluation for nonarthritic hip disease</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>movement pattern training</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>standard of care</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>3-week wait period</Name></Intervention></Interventions></InterventionsControlByRegimen><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>standard-of-care</Name></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1153018" type="Company"><TargetEntity id="5045111468" type="organizationId">Foundation for Physical Therapy Inc</TargetEntity></SourceEntity><SourceEntity id="1160134" type="Company"><TargetEntity id="5044186705" type="organizationId">Washington University Schoolof Medicine in ST Louis</TargetEntity></SourceEntity><SourceEntity id="20649" type="Company"><TargetEntity id="5000861728" type="organizationId">Ohio State University</TargetEntity></SourceEntity><SourceEntity id="542" type="ciIndication"><TargetEntity id="10003285" type="MEDDRA"></TargetEntity><TargetEntity id="D007592" type="MeSH"></TargetEntity><TargetEntity id="-428607579" type="omicsDisease"></TargetEntity><TargetEntity id="2295" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="20649">Ohio State University</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1153018">Foundation for Physical Therapy, Inc.</Company><Company id="1160134">Washington University School of Medicine, US</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Behavioral intervention</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>96</PatientCountEnrollment><DateStart>2018-02-27T00:00:00Z</DateStart><DateEnd type="estimated">2019-12-31T00:00:00Z</DateEnd><DateChangeLast>2018-10-13T16:34:11Z</DateChangeLast><DateAdded>2018-05-29T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Ohio State University</Affiliation><Email>stephanie.distasi@osumc.edu</Email><Name>Stephanie Di Stasi</Name><Phone>614-685-9779</Phone></Contact><Contact type="Scientific contact"><Affiliation>Ohio State University</Affiliation><Name>Stephanie Di Stasi</Name></Contact><Contact type="Public contact"><Email>brown.4119@osu.edu</Email><Name>Lindsey Brown</Name><Phone>614-685-9777</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Over 18 years old NAHD diagnosis&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Osteoporosis or rheumatoid arthritis&lt;/li&gt;&lt;li&gt;Systemic health condition&lt;/li&gt;&lt;li&gt;Legal representative required for treatment decisions&lt;/li&gt;&lt;li&gt;Bilateral symptoms&lt;/li&gt;&lt;li&gt;Current spine, hip, knee, or ankle surgery or major injury&lt;/li&gt;&lt;li&gt;Pregnancy&lt;/li&gt;&lt;li&gt;Total hip arthroplasty candidate (Tonnis grade&amp;gt; two)&lt;/li&gt;&lt;li&gt;Periacetabular osteotomy candidate (lateral center edge angle&amp;lt; 20, anterior center edge angle &amp;lt; 18, acetabular index  &amp;gt; ten)&lt;/li&gt;&lt;li&gt;Participants with history of spine, hip, knee, or ankle surgery or major injury will be evaluated by the physician to determine appropriateness for evaluation (and treatment) by a physical therapist&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Treatment plan: participants will indicate their planned treatment(s)</Description><Timeframe>1 day</Timeframe></Measure><Measure><Description>Decision Conflict: participants will report decision conflict related to their treatment plan</Description><Timeframe>1 day</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Change in movement mechanics: three-dimensional movement mechanics will be collected during functional tasks including walking and rising from a chair</Description><Timeframe>4 weeks</Timeframe></Measure><Measure><Description>Change in patient-reported hip function: participants will complete validated, reliable surveys for hip function (hip outcome score, 33-item international hip outcome tool)</Description><Timeframe>4 weeks</Timeframe></Measure><Measure><Description>Changes in provider protocol opinions: qualitative interviews will be conducted with study providers both before participant enrollment and after study completion to collect information on how they feel about the: evaluation protocol(s) and; treatment/wait period protocols</Description><Timeframe>15 months</Timeframe></Measure><Measure><Description>Decision conflict: participants will report decision conflict related to their treatment plan</Description><Timeframe>4 weeks</Timeframe></Measure><Measure><Description>Participant protocol opinions: participants will be interviewed to collect information on how they feel about the: evaluation protocol(s) and; treatment/wait period protocols</Description><Timeframe>4 weeks</Timeframe></Measure><Measure><Description>Changes in hip strength: strength of hip abductors, adductors, flexors, extenders, internal and external rotators will be collected during maximal voluntary isometric contractions</Description><Timeframe>4 weeks</Timeframe></Measure><Measure><Description>Decision regret: participants will report decision regret related to their treatment plans</Description><Timeframe>4 weeks</Timeframe></Measure><Measure><Description>Decision regret: participants will report decision regret related to their treatment plans</Description><Timeframe>Day of enrollment, after all evaluations are complete</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The investigators aim to understand how interdisciplinary care influences decisions,      expectations, and outcomes for patients with non-arthritic hip disease (NAHD). &lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients      presenting to the &lt;ulink linkType="Company" linkID="1108675"&gt;Ohio State University Wexner medical center&lt;/ulink&gt; (OSUWMC) hip preservation      clinic will be approached for participation. All participants will proceed with their      scheduled, standard-care physician evaluation. Participants without NAHD will be excluded.      Participants will then be randomized to receive a same-day physical therapist (PT)      evaluation. This PT evaluation is not a standard-care practice in the clinic, this is added      for research. All participants will complete expectation surveys before and after their      evaluation(s). The clinicians will discuss their recommended plan with the patient and the      patient will record a final treatment decision and outcome expectations. Participants will      then be randomized to either receive posture and movement training (PMT) for 3 weeks or      undergo a 3-week wait period. All participants will be required to withhold any treatment      during this 3-week period (except PMT in the PMT group). The 3-week wait period for the      no-PMT group is aligned with current clinical processes for time from physician evaluation to      start of treatment. All participants may proceed with any further interventions (including      PMT) after the 3-week period, but none will be provided/required as part of research.      Patient-reported outcomes and clinical tests will be recorded before and after the 3-week      period, and 3 and 6 months later. Adding a PT evaluation to the physician visit provides no      additional risk because the PT evaluation includes similar clinical tests to the physician      and movement analysis during tasks participants complete during daily life. &lt;br/&gt;Clinical tests      before/after the 3-week intervention period may produce muscle soreness that should resolve      within 2 days. Understanding how interdisciplinary care influences expectations and outcomes      can inform clinicians regarding the effectiveness of interdisciplinary collaboration.&lt;/para&gt;&lt;para&gt;The clinical evaluation by the physician is standard-of-care and performed as part of      potential participants' scheduled appointment. Participants in this study will complete a      HIPAA authorization to allow data from their clinical evaluation by the physician to be      utilized for this study, including any imaging the physician used in their clinical      evaluation and the evaluation note entered into the participant's electronic health record.      The physician notes are standardized, allowing streamlined data analysis from the electronic      health record.&lt;/para&gt;&lt;para&gt;Participants will receive an Interdisciplinary evaluation for nonarthritic hip disease from a hip arthroscopist, followed by an examination from a physical therapist, and then will participate in a shared decision-making process with both providers to determine a plan of care. The hip arthroscopist will conduct his or her standard-care evaluation including subjective interview, patient history, imaging, and physical examination. The physical therapist will conduct an assessment of posture and movement during sitting, standing, squatting, and walking. After providers discuss their findings, they will discuss the plan of care with the participant.&lt;br/&gt;Participants will receive a standard-of-care evaluation from a hip arthroscopist who will then determine the plan of care with the participant.&lt;/para&gt;&lt;para&gt;Research activities to occur the same day as the informed consent process include      randomization to receive or not receive a clinical evaluation by a physical therapist along      with surveys for treatment decisions, expected outcomes, and patient-reported function. A      small sub-group of patients will also complete interviews to identify how they felt about      their evaluation that day. The HIPAA authorization will also allow the data from the physical      therapy evaluation and any subsequent posture and movement training at OSUWMC to be utilized      for this study.&lt;/para&gt;&lt;para&gt;Regardless of randomization to receive or not receive a same-day physical therapy evaluation      in the physician clinic, all participants will be randomized to receive posture and movement      training (PMT) or undergo a 3-week wait period. Participants who are randomized to receive      PMT as part of this research study will schedule based on their availability, twice weekly      for 3 weeks with an OSUWMC sports medicine physical therapist who also hold IRB-approved      status as research personnel. Participants will be made aware during the informed consent      process that any PMT they receive as part of this study will be their responsibility to pay      for using either self-pay or insurance-based methods.&lt;/para&gt;&lt;para&gt;Participants who refuse randomization to receive PMT will be offered to participate in the      observational group. These participants proceed with the same baseline and follow-up testing,      but continue with their treatment-of-choice rather than an assigned treatment during the      3-week intervention period. Participants may proceed with any treatment-of-choice, which may or may not have been recommended by their health care provider(s). Treatments will be recorded, but not controlled.&lt;/para&gt;&lt;para&gt;All participants will complete baseline and follow-up biomechanical and clinical follow-up      testing in the motion analysis and performance laboratory. Biomechanical testing involves      using three-dimensional motion capture techniques to analyze movement during three functional tasks      including walking, sit-to-stand, and a forward tap-down. Clinical testing involves obtaining      anthropometric measures, hip strength, patient-reported function, and planned treatment      decisions with respective expected outcomes. A small sub-group of patients will also complete      interviews at these testing sessions to identify how they feel about the intervention (wait      or posture and movement training).&lt;/para&gt;&lt;para&gt;Posture and movement training involves the physical therapist prescribing therapeutic      exercises and activities to improve posture and movement (Harris-Hayes 2016), focusing      heavily on extrinsic cueing (Benjaminse 2015). Therapeutic exercises and activities will be      individualized based on the participant's presentation and will progress according to pain      and quality of movement from double-leg to single-leg activities and from functional to more      dynamic tasks.&lt;/para&gt;&lt;para&gt;      Participants who are randomized to undergo a 3-week wait period will be required to withhold      any treatment during the 3-week wait period. These participants will complete the same      testing as the participants in the PMT group (see next paragraph). These participants will      not receive any intervention during the 3-week wait period; however, after their first      follow-up testing session (within 1 week of completing the 3-week wait period), these      participants may proceed with any intervention of their choice. The participants in the PMT      group may also proceed with any intervention after their first follow-up testing session.      These follow-up interventions will not be provided or required as part of the research study,      but participants will be asked to report if they completed any follow-up interventions      between their first follow-up testing session and their 3month and 6month follow-up testing      sessions.&lt;/para&gt;&lt;para&gt;Participants will receive six training sessions with a physical therapist over a 3-week period. Physical therapists will lead participants through an intervention protocol to normalize seated and standing posture and function movement. Verbal, visual, and tactile cues, along with strengthening exercises will be provided to train posture and movement.&lt;/para&gt;&lt;para&gt;Follow-up testing will occur within 1-week of completing the 3-week intervention period. At      this point, participants in both the PMT and no-PMT groups may proceed with any intervention      (ie, surgery, injection, physical therapy). All participants will perform additional      follow-up testing at 3- and 6-months post-intervention.&lt;/para&gt;&lt;para&gt;Qualitative interviews will be conducted to evaluate how physicians and physical therapists      involved in the study feel about the evaluation and treatment protocols.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>The Ohio State University Wexner Medical Center Jameson Crane Sports Medicine Institute</Name><Address1>Columbus</Address1><Address2>Ohio</Address2><Address3>43202</Address3><CountrySubDivision code="OH">Ohio</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>angela.pedroza@osumc.edu</Email><Name>Angela Pedroza</Name><Phone>614-293-7952</Phone></Contact><Contact type="Facility investigator"><Name>Stephanie Di Stasi</Name></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Pain</Disease><PatientSegments><PatientSegment><PatientSegment id="8413">Subjects with Somatic Pain</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Other musculoskeletal disease</Disease><PatientSegments><PatientSegment><PatientSegment id="18266">Subjects with specific disease</PatientSegment><SubSegments><SubSegment id="16007">Subjects with Joint Disorder</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03519087</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Pain" id="26038"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Pain" id="34784"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Other musculoskeletal disease" id="45597"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Other musculoskeletal disease" id="46368"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Pain" id="25959"><Endpoint>Assessment of Functional Disability/Physical Function</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="34784"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Other musculoskeletal disease" id="42991"><Endpoint>Assessment of Functional Disability/Physical Function</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Other musculoskeletal disease" id="46368"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Pain" id="25959"><Endpoint>Assessment of Functional Disability/Physical Function</Endpoint></OtherEndpoint><OtherEndpoint disease="Pain" id="34784"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></OtherEndpoint><OtherEndpoint disease="Other musculoskeletal disease" id="42991"><Endpoint>Assessment of Functional Disability/Physical Function</Endpoint></OtherEndpoint><OtherEndpoint disease="Other musculoskeletal disease" id="46368"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Pain" id="22125"><Criterion>Subjects with Somatic Pain</Criterion></Inclusion><Inclusion disease="Pain" id="22189"><Criterion>Conditions Associated with Pain</Criterion><SubCriteria><SubCriterion disease="Pain" id="22207">Subjects with musculoskeletal disorder/injury associated pain</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Other musculoskeletal disease" id="35079"><Criterion>Subjects with specific disease</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Pain" id="20112"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Pain" id="20119"><Criterion>Subjects co-morbid with inflammatory disorders</Criterion></Exclusion><Exclusion disease="Pain" id="20173"><Criterion>Subjects with History/ Scheduled to Undergo Other Therapy/Procedures</Criterion><SubCriteria><SubCriterion disease="Pain" id="20177">Subjects with history/scheduled to undergo surgery</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="20182"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Pain" id="20186">Protocol specified exclusion criteria for women</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Other musculoskeletal disease" id="24023"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Other musculoskeletal disease" id="24165">Subjects with Autoimmune inflammatory disease</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Other musculoskeletal disease" id="24089"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Other musculoskeletal disease" id="24185"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion></Exclusion><Exclusion disease="Other musculoskeletal disease" id="24962"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Other musculoskeletal disease" id="24043">Pregnant/lactating women</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="28333"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2019-06-30T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2018-03-27T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2018-05-29T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="351562"><TitleDisplay>Drug Resistance Among Asymptomatic Infection</TitleDisplay><TitleOfficial>Assessment of Drug Resistance Molecular Markers in Asymptomatic Malaria Among Migrant Workers in Myanmar</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03648411</Identifier><Identifier type="Organisational Study">DMR_2018-108</Identifier></Identifiers><Indications><Indication id="268">Plasmodium infection</Indication></Indications><BiomarkerNames><BiomarkerName id="40288" role="Disease marker" type="Genomic;Proteomic">Plasmodium falciparum dihydropteroate synthetase</BiomarkerName><BiomarkerName id="44212" role="Disease marker" type="Genomic;Proteomic">Plasmodium falciparum dihydrofolate reductase</BiomarkerName></BiomarkerNames><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1084838" type="Company"><TargetEntity id="5065358233" type="organizationId">National Malaria Control Programme Myanmar</TargetEntity></SourceEntity><SourceEntity id="1120822" type="Company"><TargetEntity id="5050659266" type="organizationId">Department of Medical Research</TargetEntity></SourceEntity><SourceEntity id="268" type="ciIndication"><TargetEntity id="10025487" type="MEDDRA"></TargetEntity><TargetEntity id="673" type="ORPHANET"></TargetEntity><TargetEntity id="-2144313480" type="omicsDisease"></TargetEntity><TargetEntity id="850" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>2</NumberOfSites><CompaniesSponsor><Company id="1120822">Department of Medical Research, Lower Myanmar</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1084838">National Malaria Control Program, Myanmar</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category><Category>Dietary supplement</Category><Category>Behavioral intervention</Category></TrialCategories><TermsDesign><Term>Cross-sectional</Term><Term>Defined Population</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>760</PatientCountEnrollment><DateStart>2019-01-12T00:00:00Z</DateStart><DateEnd type="estimated">2019-12-30T00:00:00Z</DateEnd><DateChangeLast>2019-02-08T05:27:02Z</DateChangeLast><DateAdded>2018-09-11T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Email>drmhnyunt@dmr-mm.org</Email><Extension>128</Extension><Name>MYAT H NYUNT, PhD</Name><Phone>+951-375447</Phone></Contact><Contact type="Scientific contact"><Affiliation>Department of Medical Research</Affiliation><Name>Myat H Nyunt, PhD</Name></Contact><Contact type="Public contact"><Email>aungthi08@gmail.com</Email><Name>AUNG THI, MSc</Name><Phone>+951-128749</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Age &gt; 6 year&lt;/li&gt;&lt;li&gt;Migrant population (moving from their normal residence place and working at a new place such as forest related activities, gold-mines or plantation sites for &gt; 3 months to  three years)&lt;/li&gt;&lt;li&gt;Both sex&lt;/li&gt;&lt;li&gt;Participant who give informed-consent to participate the study&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Known clinical malaria cases regardless of the species detected&lt;/li&gt;&lt;li&gt;Patients with clinical symptoms of malaria at the time of examination&lt;/li&gt;&lt;li&gt;Known history of malaria within 14 days&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Prevalence of the asymptomatic infection among the study population: number of the hidden malaria cases by RDT, microscopy or nested PCR (molecular method)</Description><Timeframe>1 week</Timeframe></Measure><Measure><Description>Proportion of the drug resistance molecular markers among asymptomatic infections: among the asymptomatic cases, molecular markers will be analyzed (K13 and pfmdr1 copy number for falciparum and pvcrt-o, pvmdr1, pvdhps and pvdhfr gene analysis for vivax cases by Sanger Sequencing</Description><Timeframe>3 months</Timeframe></Measure></MeasuresPrimary><MeasureSecondary></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This is a cross-sectional study conducted in selected two sentinel sites for assessment of drug      resistance falciparum and vivax among asymptomatic infection in migrant workers in Myanmar.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Migrant population will be enrolled and observed. In this study, asymptomatic infections are screened by rapid diagnostic test, microscopy and molecular methods.  Investigators will use the comparison between the two sentinel sites by the name of Shwegyin and Pinlebu. Investigators will compare the prevalence of asymptomatic infection between these two sites. Then proportion of the drug resistance molecular markers will be compared.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Burma"><Sites><Site><Name>Department of Medical Research</Name><Contacts></Contacts></Site><Site><Name>Dr. Myat Phone Kyaw</Name><Address1>Yangon</Address1><Address3>11191</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>kyaw606@gmail.com</Email><Extension>305</Extension><Name>Myat P Kyaw, PhD</Name><Phone>+951- 375457</Phone></Contact><Contact type="Facility contact backup"><Email>drmhnyunt@gmail.com</Email><Extension>305</Extension><Name>Myat H Nyunt, MMedSc</Name><Phone>+951-375447</Phone></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Plasmodium infection</Disease><PatientSegments><PatientSegment><PatientSegment id="10400">Subjects at risk of developing disease</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="11913">Others</PatientSegment><SubSegments><SubSegment id="10417">Pediatric subjects</SubSegment><SubSegment id="10419">Healthy Subjects</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03648411</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Plasmodium infection" id="16518"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Plasmodium infection" id="16523"><Endpoint>Protocol Specified Other Endpoints</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Plasmodium infection" id="16489"><Endpoint>Assessment of Anti-malarial Resistance</Endpoint><SubEndpoints><SubEndpoint disease="Plasmodium infection" id="16490">Assessment of drug resistance markers</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Plasmodium infection" id="15442"><Criterion>Subjects at Risk of Developing Disease</Criterion></Inclusion><Inclusion disease="Plasmodium infection" id="15470"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Plasmodium infection" id="15471">Pediatric subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Plasmodium infection" id="34740"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="Plasmodium infection" id="15465">Healthy Subjects</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Plasmodium infection" id="12846"><Criterion>Subjects with Symptomatic Malaria</Criterion></Exclusion><Exclusion disease="Plasmodium infection" id="12869"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2019-08-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2018-08-23T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2018-09-11T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2019-02-08T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="372425"><TitleDisplay>Post-Operative Spinal Biomechanics Changes Of Intra-Spinal Tumor Research</TitleDisplay><TitleOfficial>Post-Operative Spinal Biomechanics Changes Of Intra-Spinal Tumor Research</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Other">ChiCTR1900021542</Identifier></Identifiers><Indications><Indication id="761">Spinal cord tumor</Indication></Indications><BiomarkerNames><BiomarkerName id="1289" role="Therapeutic effect marker" type="Structural (imaging)">Tumor mass</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Surgical reconstruction</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1062375" type="Company"><TargetEntity id="5035553768" type="organizationId">Huashan Hospital</TargetEntity></SourceEntity><SourceEntity id="761" type="ciIndication"><TargetEntity id="C72" type="ICD10"></TargetEntity><TargetEntity id="10062261" type="MEDDRA"></TargetEntity><TargetEntity id="D013120" type="MeSH"></TargetEntity><TargetEntity id="-1776922319" type="omicsDisease"></TargetEntity><TargetEntity id="3279" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><NumberOfSites>4</NumberOfSites><CompaniesSponsor><Company id="1062375">Huashan Hospital</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>No Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>240</PatientCountEnrollment><DateStart>2019-06-01T00:00:00Z</DateStart><DateEnd type="estimated">2023-05-30T00:00:00Z</DateEnd><DateChangeLast>2019-03-12T07:46:11Z</DateChangeLast><DateAdded>2019-03-12T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Email>wilmentan@163.com</Email><Name>Bo Tan</Name><Phone>+86 18665454270</Phone></Contact><Contact type="Scientific contact"><Affiliation>Huashan Hospital, Affiliated to Fudan University</Affiliation><Email>xierong3034@126.com</Email><Name>Xiaoming Che</Name><Phone>+86 15692158888</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients have cervical intra-spinal tumor with good generation condition, and are willing to accept further treatment&lt;/li&gt;&lt;li&gt;Patients without severe spinal deformities, cervical instability or structural damage&lt;/li&gt;&lt;li&gt;Patients have focal tumor with limited involvement and dont have any post-operative unstable risk factors for cervical instability&lt;/li&gt;&lt;li&gt;Patients dont have other severe complications or comorbidities&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Patients have strong and commonly accepted indications for reconstruction after tumor resection, including:&lt;ul&gt;&lt;li&gt;Relative translation of vertebra in sagittal plane &gt; 3.5 mm&lt;/li&gt;&lt;li&gt;Angulation of one vertebra to another &gt; 11 degree in resting condition&lt;/li&gt;&lt;li&gt;Tumors invading facet joints, pedicles or two of three columns&lt;/li&gt;&lt;li&gt;Severe kyphosis, scoliosis, sagittal imbalance or vertebra collapse&lt;/li&gt;&lt;li&gt;Any damage to atlanto-axial joints&lt;/li&gt;&lt;li&gt;Surgery requires removal of wide range of muscles and ligaments; patients with severe osteoporosis (T&amp;lt;1.5); patients with tumor involving cervical-thoracic junction that requires total laminectomy; syringomyelia development; patients with &gt;/= 2 of the above conditions&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Size of tumor</Description></Measure><Measure><Description>Structural damage</Description></Measure><Measure><Description>Cobb angle of tumor related segments</Description></Measure><Measure><Description>C2-7SVA</Description></Measure><Measure><Description>Cervical lordosis</Description></Measure><Measure><Description>Chin-brow vertical angle (CBVA)</Description></Measure><Measure><Description>JOA score</Description></Measure><Measure><Description>NDI score</Description></Measure><Measure><Description>SINS score</Description></Measure><Measure><Description>FIM score</Description></Measure><Measure><Description>Pfirrman's grading for lumbar disc degeneration</Description></Measure><Measure><Description>Muscle tension</Description></Measure></MeasuresPrimary><MeasureSecondary></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This study aims to identify the underlying effect of cervical intra-spinal tumor on biomechanics of the spinal cord, which guides the indication and methods of surgical treatment.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;The study consists  of two arms:&lt;br/&gt;Arm 1: patients will receive post-operative surgical reconstruction.&lt;br/&gt;Arm 2: patients will not receive post-operative reconstruction.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="China"><Sites><Site><Name>Huashan Hospital, affiliated to Fudan University</Name><Address2>Shanghai</Address2><CountrySubDivision>Shanghai</CountrySubDivision><Contacts></Contacts></Site><Site><Name>West China Hospital, Sichuan University</Name><Address2>Sichuan</Address2><CountrySubDivision>Sichuan</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Xuanwu Hospital, Capital Medical University</Name><Address2>Beijing</Address2><CountrySubDivision>Beijing</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Beijing Tiantan Hospital, Capital Medical University</Name><Address2>Beijing</Address2><CountrySubDivision>Beijing</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Beijing Tsinghua Changgung Hospital</Name><Address2>Beijing</Address2><CountrySubDivision>Beijing</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Second Affiliated Hospital Of Zhejiang University School Of Medicine</Name><Address2>Zhejiang</Address2><CountrySubDivision>Zhejiang</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms></PatientSegmentTerms><TrialRegistries><Registry><Name id="1007">Chinese Clinical Trials Registry (ChiCTR)</Name><Identifiers><Identifier>ChiCTR1900021542</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Bone tumor" id="11471"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Bone tumor" id="11520"><Endpoint>Assessment of Morbidity Rates</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Bone tumor" id="11528"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Bone tumor" id="11533">Assessment of tumor burden</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Bone tumor" id="45178"><Endpoint>Clinical Assessments</Endpoint></PrimaryEndpoint></PrimaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Bone tumor" id="7158"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Bone tumor" id="34909"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Bone tumor" id="7164">Subjects able to comply with the study protocol procedures/ requirements</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Bone tumor" id="8740"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Bone tumor" id="8750"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion></Exclusion><Exclusion disease="Bone tumor" id="8767"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion></Exclusion><Exclusion disease="Bone tumor" id="8779"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Bone tumor" id="8788">Subjects failing to meet protocol specified criteria</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2019-03-12T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial></ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialRecordsOutput>